## <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

### **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Provided in the methods section, paragraph named "Flow cytometry and intracellular cytokine staining", Line 191-196 and Table 2	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		n/a
<b>Primary cultures:</b> Provide species, strain, sex of origin, genetic modification status.	Provided in the methods section, paragraph named "Patients" and Table 1	
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
<b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID		n/a
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a
<b>Model organisms:</b> Provide Accession number in repository (where relevant) <b>OR</b> RRID		n/a
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		n/a
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Provided in the methods section, paragraph named "Ethical statement", line 132-135 and Footnote section, line 433-439	
Provide statement confirming informed consent obtained from study participants.	Provided in the methods section, paragraph named "Ethical statement", line 135 and Footnote section, line	

438-439

Provided in "Table 1".

Report on age and sex for all study participants.

# Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.		n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	Provided in the methods section, paragraph named	
by-step protocols are available.	"Sample collection and processing", Cell isolation and culture, Flow cytometry and intracellular cytokine	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		
done <b>, or</b> if they were not carried out.		
Sample size determination	Provided in the methods section, paragraph named "Patients" line 138 and Figure legend	
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria	Provided in the methods section, paragraph named "Patients" line 138-152	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Provided in Figure legend	
Define whether data describe technical or biological replicates		n/a
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Provided in the methods section, paragraph named "Ethical statement", line 132-135 and Footnote section "Ethical statement", line 433-439	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		n/a

### **Analysis**

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		n/a
Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Provided in the methods section, paragraph named "Statistical analysis", line 213-218, Table1 and Figure legend.	
Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Provided in Data sharing statement	
If data are publicly available, provide accession number in repository or DOI or URL.	Provided in Data sharing statement	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Provided in Data sharing statement	
Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		n/a
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a

# **Reporting**

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: http://dx.doi.org/10.21037/atm-20-7181